Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B8572-ADC
- Development stage
- Preclinical
- Lead developer
- Nanolattix
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
B8572-ADC is a preclinical-stage bispecific antibody-drug conjugate (ADC) being developed by Shanxi Naan Biotechnology. It is designed to target multiple antigens simultaneously, potentially enhancing tumor specificity and overcoming resistance mechanisms common in monovalent ADCs. The drug is currently being investigated for the treatment of various solid tumors, including lung cancer, gastric cancer, and breast cancer. It is administered via intravenous injection.
Beyond the preview
Go deeper on B8572-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B8572-ADC.